From a molecular therapeutic perspective, Relafen 750, containing naproxen, operates as a potent anti-inflammatory drug. Its mechanism entails the blocking of cyclooxygenase catalysts , specifically COX-1 and COX-2, thereby lowering the synthesis of prostaglandins . The resultant decrease in prostaglandin amounts results in a alleviation of pain an